The Efficacy of Vildagliptin in Korean Patients with Type 2 Diabetes
暂无分享,去创建一个
[1] Hun‐Sung Kim,et al. Predictive Clinical Parameters and Glycemic Efficacy of Vildagliptin Treatment in Korean Subjects with Type 2 Diabetes , 2013, Diabetes & metabolism journal.
[2] K. Goossen,et al. Longer term safety of dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta‐analysis , 2012, Diabetes, obesity & metabolism.
[3] André Scheen,et al. RECOMMANDATIONS 2012 EN DIABÉTOLOGIE: Prise en charge de l'hyperglycémie dans le diabète de type 2: une approche centrée sur le patient , 2012 .
[4] Masaya Sakamoto,et al. Comparison of vildagliptin twice daily vs. sitagliptin once daily using continuous glucose monitoring (CGM): Crossover pilot study (J-VICTORIA study) , 2012, Cardiovascular Diabetology.
[5] S. Dejager,et al. Impact of Insulin Resistance, Body Mass Index, Disease Duration, and Duration of Metformin Use on the Efficacy of Vildagliptin , 2012, Diabetes Therapy.
[6] S. Dejager,et al. Evidence to support the use of vildagliptin monotherapy in the treatment of type 2 diabetes mellitus , 2012, Vascular health and risk management.
[7] D. Matthews,et al. Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach , 2012, Diabetes Care.
[8] T. Oh,et al. Comparison of Vildagliptin-Metformin and Glimepiride-Metformin Treatments in Type 2 Diabetic Patients , 2011, Diabetes & metabolism journal.
[9] S. Dejager,et al. Mechanisms of action of the dipeptidyl peptidase‐4 inhibitor vildagliptin in humans , 2011, Diabetes, obesity & metabolism.
[10] A. Corsini,et al. Pharmacology of Dipeptidyl Peptidase-4 Inhibitors , 2011, Drugs.
[11] G. Nijpels,et al. Beta cell function following 1 year vildagliptin or placebo treatment and after 12 week washout in drug-naive patients with type 2 diabetes and mild hyperglycaemia: a randomised controlled trial , 2011, Diabetologia.
[12] S. Heller,et al. Hypoglycemia and Cardiovascular Risks , 2011, Diabetes Care.
[13] C. Ahn,et al. Predictive Clinical Parameters for the Therapeutic Efficacy of Sitagliptin in Korean Type 2 Diabetes Mellitus , 2011, Diabetes & metabolism journal.
[14] B. Zinman,et al. Vildagliptin add‐on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2‐year study , 2010, Diabetes, obesity & metabolism.
[15] Y. Iwamoto,et al. Efficacy and safety of vildagliptin and voglibose in Japanese patients with type 2 diabetes: a 12-week, randomized, double-blind, active-controlled study , 2010, Diabetes, obesity & metabolism.
[16] B. Zinman,et al. Changes in Prandial Glucagon Levels After a 2-Year Treatment With Vildagliptin or Glimepiride in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy , 2010, Diabetes Care.
[17] J. Foley,et al. Efficacy and Safety Comparison Between the DPP-4 Inhibitor Vildagliptin and the Sulfonylurea Gliclazide After Two Years of Monotherapy in Drug-naïve Patients with Type 2 Diabetes , 2009, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.
[18] S. Dejager,et al. Comparison of vildagliptin and metformin monotherapy in elderly patients with type 2 diabetes: a 24‐week, double‐blind, randomized trial , 2009, Diabetes, obesity & metabolism.
[19] P. Nilsson,et al. Evidence that vildagliptin attenuates deterioration of glycaemic control during 2‐year treatment of patients with type 2 diabetes and mild hyperglycaemia * , 2008, Diabetes, obesity & metabolism.
[20] S. Dejager,et al. Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naïve patients with type 2 diabetes: comparison with metformin. , 2008, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.
[21] J. Foley,et al. Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24‐week, double‐blind, randomized trial , 2008, Diabetic medicine : a journal of the British Diabetic Association.
[22] J. Foley,et al. The islet enhancer vildagliptin: mechanisms of improved glucose metabolism , 2008, International journal of clinical practice. Supplement.
[23] Y. Terauchi,et al. Factors associated with the glucose-lowering effect of vildagliptin identified from the results of the oral glucose tolerance test in Japanese patients with type 2 diabetes. , 2013, Endocrine journal.